lucius卢修斯 必妥维比克恩丙诺Bictegravir/Emtricitabine/Tenofovir AlafenamideHIV-1感染

必妥维比克恩丙诺

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Bictegravir/Emtricitabine/

老挝国家食药监局批准上市

Tenofovir Alafenamide

老挝国家药检所检测认证

Composition:

LUCiUS

HIV-1感染

e es abe contains 50 mg of Bictegravir
gof Bictegravir sodiami 100 mnat

etivalent to 28 rae of lenofoviralafenaide firmarale).

PHARMACEUTICALS

LuciBet is a three-drug combination of bieleorau
strand transfer inbibitoe/ NSTL and emiricitbine FTC
IHIV-Dinlegrase
and tenofovir alafenaride (TAF),both HIV-| nuc leosi
analog reverse trasscriptase inhibitors (NRTIs), znd
indicated as a complete resimen for the ltvatmant of

LUCIBET

infection in adalts and nadiatrie nstients oeirhine at lent
pace e curtent antiretrovaral re

éral regiraen in those w

Bictegravir/Emtricitabine
/ Tenofovir Alafenamide

FDA批准

*Recommended dotss

ecommended dosage in adults and pedatric pallents

50mg/200mg/25mg

ot without food

Rx Onl

pet mL) on à sté ble antiretroviral régimen wot no smoe
sabstitutions zssoeiated with resistance to the individual
components of Luc Bet. One tablet onee daily with of
sorage: in a dry place and slore at 20 C 10.9
eep medicine out of te

权威认证

PLEASP SEE PACKACE INSERT
Mannfactured and Marketed
LUCIUS

Thongmang village. Xaythaty district, Vientiane Capita
www.luciasla
war ml ng : Lo be seid og retall on prescrigten of registered

plysiciass only, and no

30 Tablets

口碑质量

适应症:

适用于治疗体重至少14kg的成人和儿童患者的HIV-1感染,该患者:
1、没有抗逆转录病毒治疗史或
2、在病毒学抑制(HIV-1 RNA低于每毫升50个单位)的患者中,用稳定的抗逆
转录病毒方案取代目前的抗逆转录酶病毒方案,该方案没有已知或疑似与比
克替拉韦钠或替诺福韦耐药性相关的替代方案。
推荐剂量:
1、体重至少25公斤的成人和儿科患者,或接受慢性血液透析的估计肌酐清除
率低于15毫升/分钟的病毒学抑制的推荐剂量:每日一次,每次一片。
2、在稳定的抗逆转录病毒治疗方案中,病毒抑制(HIV-1 RNA低于每毫升50个
单位)的推荐剂量:每日一次,每次一片。